20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Investors continue to show interest in the medical possibilities of cannabis-derived cannabidiol, or CBD, eagerly watching Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) as it begins patient trials on a CBD-infused skin gel aimed at treating Fragile X syndrome.
Canaccord Genuity reiterated a bullish stance on the stock Thursday after meeting with Zynerba CEO Armando Anido.
The Analyst
Sumant Kulkarni reiterated a Buy rating on Zynerba with an $18 price target.
Need more cannabis news? Check out all of our coverage here.
The Thesis
“We believe the stock presents a significant opportunity for risk-tolerant investors,” Kulkarni said in the note. (See his track record here.)
The 14-week trial for the Fragile X transdermal skin gel, Zygel, is on track for a data readout in the second half of 2019, the analyst said.
If the results show some success, Zynerba hopes to gain approval in 2021.
Canaccord Genuity is modeling a 50% probability of approval for the FXS treatment.
The company is also expecting open-label data on the use of the drug for developmental and epileptic encephalopathies in the third quarter of 2019, but the trial for Fragile X treatment is the bigger inflection point, Kulkarni said.
Price Action
Zynerba shares were up 3.07% on Friday morning to $13.30.
Related Links:
Zynerba Advances Cannabidiol Treatment With New Patent Win
FDA Public Hearing About CBDs Prescribes Caution, Bearishness, and Deliberation
Photo courtesy of Zynerba.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!